References to Primary Literature
- Engle, A Roberts, J Burch, JA Rheumatoid Arthritis in Adults in the US 1960–62. Vital and Health Statistics Series II From the National Health Survey No: 17 National Center for Health Statistics Washington, D.C 1986.
- Shearn, MA Arthritis and Musculoskeletal Disorders Current Medical Diagnosis and Treatment 1987 Krupp, MA, Schroeder, SA, Tierney, LM Appleton Lange USA 1987.
- Lewis, AJ Glaser, KB Sturm, RJ Mölnar, KK Bansbach, CC Strategies for the development of new antiarthritic agents. Int. J. Immunopharmacol. 1992 14 497–504.
- McMillan, RM Walker, ERH Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. 1992 13 323–330.
- Bell, RL Young, PR Albert, D Lanni, C Summers, JB Brooks, DW Rubin, P Carter, GW The Discovery and Development of Zileuton: An Orally Active 5-Lipoxygenase Inhibitor. Int. J. Immunopharmac. 1992 14 505–510.
- Israel, E Drazen, J Pearlman, H Cohn, J Rubin, P A double-blind multicenter study of zileuton, a potent 5-lipoxygenase (5-LO) inhibitor versus placebo in the treatment of spontaneous asthma in adults. Journal of Allergy and Clinical Immunology 1992 89 236–236.
- Crawley, GC Dowell, RI Edwards, PN Foster, SJ McMillan, RM Walker, ERH Waterson, D Methoxytetrahydropyrans: A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors. J. Med. Chem. 1992 35 2600–2609.
- Moilanen, E Alanko, I Azmawi, Z Vapaatalo, H CP-66248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphponuclear leukocytes in vitro. Eicosanoids 1988 1 35.
- Wilkens, H Wilkens, J Bosse, S Kempe, F Fritz, S Frolich, J Fabel, H Effects of an inhaled PAF-antagonist (WEB-2086) on allergen-induced early and late asthmatic responses and increased bronchial responsiveness to metacholine. Am. Rev. Respir. Dis. 1991 143 A812.
- Bel, E De Smet, M Rossing, T Timmers, M Dijman, J Sterk, P The effect of a specific oral PAF antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis. 1991 143 A811.
- Dermarkarian, R Israel, E Rosenberg, M Jansen, A Danzig, M Fourre, J Drazen, J The effect of Sch-37370, a dual platelet activating factor and histamine antagonist on the bronchoconstriction induced in asthmatics by cold, dry air isocapnic hyperventilation. Am. Rev. Respir. Dis. 1991 143 A812.
- Kuitert, LM Hui, K Uthayarkumar, S Burke, W Newland, AC Uden, S Barnes, NC Effects of a platelet-activating factor (PAF) antagonist UK 74,505 on allergen-induced early and late response. Am. Rev. Respir. Dis. 1992 145 A292.
- Takehara, S Mikashima, H Muramoto, Y Terasawa, M Setaguchi, M Tahara, T Pharmacological Action of Y-24180, a New Specific Antagonist of Platelet Activating Factor (PAF): II. Interactions with PAF and Benzodiazepine Receptors. Prostaglandins 1990 40 571.
- Sehgal, SN Chang, JY Rapamycin: A New Immunosuppressive macrolide. SIM Industrial Microbiology NEWS 1992 230–233.
- Morris, RE Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplantation Reviews 1992 6 39–87.
- Sigal, NH Dumont, FJ Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 1992 10 519–560.
- Siekerka, JJ Hung, SH Poe, M Lin, CS Sigal, NH A cytosolic binding protein for the immunosuppressant FK506 has peptidylprolyl isomerase activity but is distinct from cyclophilin. Nature 1989 341 755–757.
- Harding, MW Galat, A Uehling, DE Schreiber, SL A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989 341 758–760.
- Bierer, BE Somers, PK Wandless, TJ Burakoff, SJ Schreiber, SL Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand. Science 1990 250 556–559.
- Schreiber, SL Crabtree, GR The mechanism of action of cyclosporin A and FK506. Immunology Today 1992 13 136–142.
- Luly, JR Mechanism-based Immunosuppressants Annual Reports in Medicinal Chemistry Academic Press, Inc. San Diego 1991 211–220 Bristol JA.
- Morris, RE Immunopharmacology of New Xenobiotic Immunosuppressive Molecules. Seminars in Nephtology 1992 12 304–314.
- Bartlett, RR Mattar, T Weithmann, U Anagnostopoulos, H Popovic, S Schleyerbach, R Leflunomide (HWA 486): A novel immunorestoring drug Therapeutic Approa ches to Inflammatory Diseases Lewis, AJ, Doherty, NS, Ackerman, NR Elsevier Science Publishing Co New York 1989 215–217.
- Makowka, L Cramer, DV Brequinar sodium: A new immunosuppressive drug for transplantation. Transplantation Science 1992 2 50–54.
- Sircar, JC Gibertsen, RB Purine nucleoside phosphorylase (PNP) inhibitors: Potentially selective immunosuppressive agents. Drugs of the Future 1988 13 653–668.
- Payan, DG Neuropeptides and inflammation: The role of substance P. Annu. Rev. Med. 1989 40 341.
- Murthy, SN Depace, DM Shah, RS Podell, R Acute effect of substance P in immunologic vasculitis in the rat colon. Peptides 1991 12 1337.
- Dinarello, CA Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991 3 941–948.
- Cerretti, DP Koslosky, CJ Mosley, B Nelson, N Van Ness, K Greenstreet, TA March, CJ Kronheim, SR Druck, T Cannizzaro, LA Huebner, K Black, RA Molecular Cloning of the Interleukin-1β Converting Enzyme. Science 1992 256 97–100.
- Thornberry, NA Bull, HG Calaycay, JR Chapman, KT Howard, AD Kostura, MJ Miller, DK Molineauz, SM Weidner, JR Aunins, J Elliston, KO Ayala, JM Casano, FJ Chin, J Ding, GJF Egger, LA Gaffney, EP Limjuco, G Palyha, OC Raju, SM Rolando, AM Salley, JP Yamin, TT Lee, TD Shively, JE MacCross, M Mumford, RA Schmidt, JA Tocci, MJ A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992 356 768–774.
- Pardi, R Inverardi, L Bender, JR Regulatory mechanisms in leukocyte adhesion: Flexible receptors for sophisticated travelers. Immunology Today 1992 13 224–230.
- Shearer, BG Sullivan, JP Carter, JP Mathew, RM Waid, P Connor, JR Patch, FJ Burch, RM Substituted 2-(aminomethyl)piperidines: A novel class of selective protein kinase C inhibitors. J. Med. Chem. 1991 34 2928.
- Madan, BR Al-Humayyad, MS Mobarok Ali, AA Action and interaction of nifedipine, indomethacin and aspirin in carrageenan-induced inflammation of the rat. Med. Sci. Res. 1989 17 191.
- Al-Tuwauri, AS Mustafa, AA Verapamil enhances the inhibitory effect of diclofenac on the chemiluminescence of human polymorphonuclear leukocytes and carrageenan-induced rat's paw oedema. Int. J. Immunopharmac. 1992 14 83.
References to Patent Literature
- Abbott Laboratories WO9201682.
- Wellcome Fdn Ltd WO9209567.
- Grüntenthal GmbH EP-468281-A.
- Abbott Laboratories US5037853.
- Pfizer Inc WO9209566.
- Du Pont Merck Pharm Co US5110831.
- Merrell Dow Pharm Inc US5109010.
- ICI Plc EP-351194-A.
- ICI Plc EP-375368-A.
- ICI Plc EP-375452-A.
- ICI Plc EP-375452-A.
- ICI Plc EP-381375-A.
- ICI Plc EP-409412-A.
- ICI Plc EP-462812-A.
- ICI Plc EP-462813-A.
- ICI Plc EP-462831-A.
- ICI Plc EP-488602-A.
- Pfizer Inc WO9205164.
- GD Searle US5082854.
- GD Searle WO9204324.
- GD Searle US5019597.
- Adir Et Co EP-463945-A.
- Green Cross Corp EP-464859-A.
- Fujisawa Pharm Co Ltd WO9119708.
- SmithKline Beecham Corp WO9119497.
- Eisai Co Ltd EP-486022-A.
- Taiho Pharm Co Ltd WO9205162.
- Pfizer Inc WO9201684.
- Abbott Laboratories US5095031.
- Abbott Laboratories WO9203132.
- Pfizer Inc WO9206088.
- Merck Frosst Canada Inc EP-468785-A.
- Merck Frosst Canada Inc EP-480708-A.
- Merck Frosst Canada Inc EP-480716-A.
- Merck Frosst Canada Inc EP-480717-A.
- Lilly Ind Ltd EP-476935-A.
- SmithKline Beecham Corp WO9205156.
- Lilly Ind Ltd EP-469833-A.
- Yoshitomi Pharm Ind Ltd EP-466125-A.
- Terumo KK EP-481891–A.
- UBE Ind Ltd EP-485984-A.
- Rhone-Poulenc Rorer SA WO9201675.
- Rhone-Poulenc Rorer Int Inc WO9204315.
- Rhone-Poulenc Rorer Int Inc WO9204321.
- Rhone-Poulenc Rorer Int Inc WO9205143.
- SmithKline Beecham Corp WO9118879.
- SmithKline Beecham Corp WO9118880.
- GD Searle & Co WO9200011.
- Yoshitomi Pharm Ind EP-480455-A.
- British Bio-Technology Ltd WO9203422.
- Pfizer Ltd WO9203434.
- Pfizer Ltd WO9204354.
- Schering Corp WO9200293.
- Schering Corp WO9206981.
- Schering Corp WO9206970.
- Schering Corp WO9206971.
- American Cyanamid Co US5077409.
- Ishihara Sangyo Kaisha Ltd EP-465913-A.
- Bristol-Myers Squibb Co EP-476682-A.
- American Home Products Corp US5078999.
- American Home Products Corp EP-470804-A.
- Fujisawa Pharm Co Ltd GB2249787-A.
- American Home Products Corp GB2247017-A.
- Merck & Co Inc EP-478235-A.
- Merck & Co Inc EP-480623-A.
- American Home Products Corp WO9205179.
- Fujisawa Pharm Co Ltd GB22465687-A.
- Merck & Co Inc US5093338.
- Merck & Co Inc WO9206992.
- Fisons Plc WO9203441.
- Fujisawa Pharm Co Ltd WO9200980.
- Fujisawa Pharm Co Ltd GB2246350-A.
- Fujisawa Pharm Co Ltd GB2247456-A.
- Fujisawa Pharm Co Ltd EP-483842-A.
- Fujisawa Pharm Co Ltd EP-484936-A.
- Vertex Pharm Inc WO9204370.
- Vertex Pharm Inc WO9200278.
- Syntex (USA) Inc US5108999.
- Merck & Co Inc EP-480713-A.
- Hoechst AG EP-479177-A.
- Du Pont Merck Pharm Co WO9200739.
- Wellcome Fdn Ltd EP-478292-A.
- Marion Merrell Dow Pharm Inc EP-475411-A.
- Merrell Dow Pharm Inc EP-471383-A.
- Merck & Co Inc US5100880.
- Merck & Co Inc EP-481671-A.
- Merck & Co Inc US5104862.
- Cortech Inc EP-465802-A.
- Sterling Winthrop Inc EP-483928-A.
- Medea Research Srl WO9208713.
- Glycomed Inc et al. WO9209563.
- University of Florida Research Fdn et al WO9209282.
- Galardy RE; Grobelny D WO920556.
- Pfizer Inc WO9206079.
- Pfizer Inc W09118899.
- Fujisawa Pharm Co EP-482539-A.
- Menarini Ind Farm Riunite Srl WO9202546.
- Sanofi EP-474561-A.
- Immunex Corp W09115577.
- Rhone-Poulenc Rorer SA WO9206114.
- SmithKline Beecham Corp WO9200968.
- SmithKline Beecham Corp WO9207567.
- SmithKline Beecham Corp WO9202220.
- SmithKline Beecham Corp WO9209203.
- Celltech Ltd, Hoechst AG WO9207585.
- Scripps Res Inst WO9204372.
- Boehringer Ingelheim Pharm Inc WO9206119.
- Center for Blood Research Lab Inc EP-488061-A.
- Glycomed Inc WO9202527.
- University of Michigan WO9207572.
- Biogen Inc WO9208489.
- Novo Nordisk AS WO9200751.
- F Hoffmann-La Roche EP-470490-A.
- Nova Pharm Corp WO9203415.
- Merrell Dow Pharm Inc EP-476645-A.
- Merrell Dow Pharm Inc EP-476658-A.
- Merrell Dow Pharm Inc EP-476646-A.
- Takeda Chem Ind Ltd EP-460488-A.